Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
Eric Chen, David M Brown, Tien P Wong, Matthew S Benz, Eric Kegley, Joel Cox, Richard H Fish, Rosa Y KimRetina Consultants of Houston, Texas, USAPurpose: Combination verteporfin photodynamic therapy (vPDT) and antivascular endothelial growth factor (anti-VEGF) therapy may decrease the need for injec...
Guardado en:
Autores principales: | Eric Chen, David M Brown, Tien P Wong, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4098c9b961ed4472a236a8e99ec3b971 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
por: Eric Chen, et al.
Publicado: (2010) -
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
por: Sinapis C, et al.
Publicado: (2011) -
Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
por: Nicola G Ghazi, et al.
Publicado: (2010) -
A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
por: Williams PD, et al.
Publicado: (2012) -
The effect of intravitreal bevacizumab (Avastin®) on ocular pulse amplitude in neovascular age-related macular degeneration
por: Ehud Rechtman, et al.
Publicado: (2011)